Home・Lista de Ações・Fate Therapeutics Inc

Fate Therapeutics Inc

Fechado

SetorSaúde

2.43 -3.57

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

2.4

Máximo

2.45

Indicadores-chave
By Trading Economics
Rendimento	1.2M -31M
Vendas	-70K 1.3M
EPS	-0.26
Margem de lucro	-2,402.848
Funcionários	161
EBITDA	14M -28M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+107.94% upside

Dividendos
By Acuity
Próximos Ganhos	10 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	71M 324M
Abertura anterior	6
Fecho anterior	2.43

Sentimento de Notícias

By Acuity

50%

163 / 340 Ranking em Healthcare

Fate Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de jul. de 2026, 19:07 UTC

Correlated Moves

Fate Therapeutics shares are lower, pressured by a notable decline in first-quarter results and broader market sentiment. They remain below the 20-day moving average.

23 de jul. de 2026, 21:11 UTC

Fate Therapeutics Inc. shares are higher in after-market hours, reflecting broader market gains. No specific company news has been identified to explain this increase.

22 de jul. de 2026, 23:46 UTC

Fate Therapeutics Inc shares are higher in after-market trading, reflecting a modest gain since Wednesday's close, despite no specific news identified.

20 de jul. de 2026, 18:26 UTC

Fate Therapeutics Inc. shares are effectively unchanged as trading remains flat. The stock has seen strong performance over the past month, nearing its recent highs.

Comparação entre Pares

Variação de preço

Fate Therapeutics Inc Previsão

Preço-alvo

By TipRanks

107.94% parte superior

Previsão para 12 meses

Média 5.24 USD 107.94%

Máximo 8 USD

Mínimo 2.2 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Fate Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para Fate Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

163 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.